Scarica l'app Stockscreener
11.55
1.53%
-0.18
Dopo l'orario di chiusura:
11.42
-0.13
-1.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.73
Aprire:
$11.8
Volume 24 ore:
1.98M
Relative Volume:
2.17
Capitalizzazione di mercato:
$796.11M
Reddito:
$46.02M
Utile/perdita netta:
$-70.80M
Rapporto P/E:
-6.3462
EPS:
-1.82
Flusso di cassa netto:
$-1.61M
1 W Prestazione:
-17.35%
1M Prestazione:
-15.07%
6M Prestazione:
+108.11%
1 anno Prestazione:
+2.39%
Intervallo 1D:
$11.45
$12.31
Intervallo di 1 settimana:
$11.25
$14.11
Portata 52W:
$3.91
$14.91
Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile
Nome
Eyepoint Pharmaceuticals Inc
Settore
Industria
Telefono
617-926-5000
Indirizzo
480 PLEASANT STREET, WATERTOWN, MA
Confronta EYPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Pharmaceuticals Inc
|
11.55 | 907.08M | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-07 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-22 | Iniziato | JP Morgan | Overweight |
| 2023-11-02 | Iniziato | Mizuho | Buy |
| 2023-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2022-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2021-01-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Ripresa | Laidlaw | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
Mostra tutto
Eyepoint Pharmaceuticals Inc Borsa (EYPT) Ultime notizie
What does recent volatility data suggest for EyePoint Pharmaceuticals Inc.IPO Watch & Community Driven Trade Alerts - newser.com
EyePoint (EYPT) Grants Stock Options to New Employees - GuruFocus
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - EyePoint Pharmaceuticals
13,500-Share Grant: EyePoint Issues Stock Options at $11.73 Exercise Price, Vesting 4 Years - Stock Titan
EyePoint: Uncompelling Non-Inferiority Strategy Vs. A Moving Aflibercept Target - Seeking Alpha
EyePoint Pharmaceuticals Sets Pricing of Its Public Stock Offering - VisionMonday.com
Is EyePoint Pharmaceuticals Inc. trending in predictive chart modelsJuly 2025 Decliners & AI Optimized Trading Strategy Guides - newser.com
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study - inkl
Is EyePoint Pharmaceuticals Inc. stock ready for breakout2025 Price Action Summary & Momentum Based Trading Ideas - newser.com
Chart based analysis of EyePoint Pharmaceuticals Inc. trends2025 Trading Recap & Real-Time Chart Breakout Alerts - newser.com
EyePoint Pharma falls on pricing $150 mln stock offering - TradingView
EYPT Sets Pricing Range for Recent Offering - GuruFocus
EyePoint prices public offering at $12.00 per share, raises $150M to boost DURAVYU™ Phase 3 clinical programs - MSN
EyePoint Pharmaceuticals prices $150 million public offering By Investing.com - Investing.com Nigeria
EyePoint Announces Pricing of Public Offering - The Manila Times
$150M Offering: EyePoint Prices 11M Shares to Advance DURAVYU Trials and Support Pipeline - Stock Titan
Eyepoint Pharmaceuticals prices public offering of 11 million shares at $12.00 per share - MarketScreener
EyePoint’s DURAVYU advances to phase 3 trials for diabetic eye disease - Investing.com Canada
EyePoint Pharmaceuticals launches $150 million public offering By Investing.com - Investing.com Nigeria
JPMorgan and Partners Manage Offering for EYPT - GuruFocus
EyePoint (EYPT) Launches $150 Million Public Share Offering - GuruFocus
EyePoint Pharmaceuticals (EYPT) Announces $150 Million Public Of - GuruFocus
EyePoint Pharmaceuticals Initiates Phase 3 Program for Duravyu to Treat Diabetic Macular Edema - MarketScreener
EyePoint Pharma slips after announcing $150 mln stock offering - TradingView
EyePoint announces proposed public offering of common stock - MSN
EyePoint Announces Proposed Public Offering of Common Stock - The Manila Times
EyePoint Pharmaceuticals launches $150 million public offering - Investing.com
Eyepoint Pharmaceuticals stock falls after $150 million share offering By Investing.com - Investing.com Australia
Eyepoint Pharmaceuticals stock falls after $150 million share offering - Investing.com
EyePoint’s DURAVYU advances to phase 3 trials for diabetic eye disease By Investing.com - Investing.com South Africa
Eyepoint Pharmaceuticals Inc files for mixed shelf size not disclosedSEC filing - MarketScreener
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program - TipRanks
EyePoint (EYPT) Advances Duravyu Phase 3 Program for Diabetic Macular Edema - GuruFocus
Eyepoint Pharmaceuticals announces Phase 3 diabetes program starting in 2026 - Traders Union
EyePoint Announces Pivotal Phase 3 Program Initiation for DURAVYU™ in Diabetic Macular Edema - The Manila Times
EyePoint Pharmaceuticals Advances DURAVYU to Phase 3 Trials for Diabetic Macular Edema and Wet AMD, First Patient Dosing Expected in Q1 2026 - Quiver Quantitative
EyePoint Pharmaceuticals, Inc. Announces Pivotal Phase 3 Program Initiation for Duravuyu in Diabetic Macular Edema - MarketScreener
Will EyePoint Pharmaceuticals Inc. stock split attract more investorsJuly 2025 PostEarnings & Verified Chart Pattern Signals - newser.com
Will earnings trigger a reversal in EyePoint Pharmaceuticals Inc.Rate Hike & Precise Swing Trade Entry Alerts - newser.com
EyePoint initiated at buy by Citi on wAMD drug potential - MSN
Using R and stats models for EyePoint Pharmaceuticals Inc. forecastingQuarterly Earnings Report & Risk Managed Investment Strategies - newser.com
Is EyePoint Pharmaceuticals Inc. (PV3B) stock a buy before new product rolloutExit Point & Momentum Based Trading Ideas - newser.com
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Eyepoint Pharmaceuticals' (EYPT) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
How EyePoint Pharmaceuticals Inc. (PV3B) stock behaves in tightening cyclesVolume Spike & Advanced Technical Signal Analysis - newser.com
Is a relief rally coming for EyePoint Pharmaceuticals Inc. holdersJuly 2025 Trade Ideas & Free Technical Confirmation Trade Alerts - newser.com
What downside risks could hit EyePoint Pharmaceuticals Inc. (PV3B) stock2025 Market Trends & Low Drawdown Investment Ideas - newser.com
Using Bollinger Bands to evaluate EyePoint Pharmaceuticals Inc.2025 EndofYear Setup & Verified Chart Pattern Signals - newser.com
What analysts say about EyePoint Pharmaceuticals Inc stockReal-Time Stock Alerts & Take Advantage of Momentum Stocks - earlytimes.in
EyePoint Pharmaceuticals Hits New 52-Week High of $14.90 - Markets Mojo
Can EyePoint Pharmaceuticals Inc. (PV3B) stock sustain margin levelsCEO Change & Daily Stock Trend Reports - newser.com
Eyepoint Pharmaceuticals Inc Azioni (EYPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Eyepoint Pharmaceuticals Inc Azioni (EYPT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Lurker Nancy | Director |
Jul 10 '25 |
Option Exercise |
0.00 |
11,111 |
0 |
216,547 |
| Duker Jay S. | President and CEO |
Jul 10 '25 |
Option Exercise |
0.00 |
16,667 |
0 |
17,653 |
| Elston George | Chief Financial Officer |
May 25 '25 |
Option Exercise |
0.00 |
7,500 |
0 |
83,050 |
| Zaderej Karen L. | Director |
May 19 '25 |
Buy |
5.99 |
5,000 |
29,950 |
36,500 |
| Zaderej Karen L. | Director |
May 16 '25 |
Buy |
5.81 |
5,000 |
29,050 |
31,500 |
| Zaderej Karen L. | Director |
May 15 '25 |
Buy |
5.47 |
5,000 |
27,350 |
26,500 |
| Zaderej Karen L. | Director |
May 14 '25 |
Buy |
5.42 |
5,000 |
27,100 |
21,500 |
| Elston George | Chief Financial Officer |
Feb 09 '25 |
Option Exercise |
0.00 |
5,834 |
0 |
75,550 |
| Lurker Nancy | Director |
Feb 09 '25 |
Option Exercise |
0.00 |
20,000 |
0 |
205,436 |
| Duker Jay S. | President and CEO |
Feb 09 '25 |
Option Exercise |
0.00 |
7,000 |
0 |
79,706 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):